Participation rates are even lower among ethnic and racial minorities and the medically underserved, who tend to have higher cancer mortality rates than the population as a whole. [5] [6] [7] Given persistent cancer health disparities in these populations, cancer clinical trial participation is increasingly an issue of social justice. Community-based participatory research (CBPR) approaches have been repeatedly recommended as a key strategy for increasing and diversifying cancer clinical trial participation and enhancing their relevance and quality. In 2006, Community-Campus Partnership for Health (CCPH) and the Education Network to Advance Cancer Clinical Trials (ENACCT) received funding from the Agency for Healthcare Research and Quality and the National Cancer Institute (NCI), along with industry and nonprofit partners, to develop the first set of national recommendations to employ CBPR approaches in multisite, phase III cancer clinical trials. The Communities as Partners in Cancer Clinical Trials: Changing Research, Practice and Policy final report, developed through a national advisory committee, two stakeholder meetings and a public vetting process, makes more than fifty detailed recom menda tions to engage communities in specific and meaningful ways throughout the cancer clinical trial process. 1 The report is the first to provide specific guidance as to how and why clinical trials should involve communities affected by cancer-from trial design to implementation to dissemination of results. This paper describes the background and rationale for the initiative, the process used to develop and disseminate the report, and the challenges and opportunities for implementing the report's community-based approaches to cancer clinical research.
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Clinical research, community-based participatory research, minority recruitment and retention, clinical trials, patient advocate, community advisory board, community-engaged research either no treatment or treatment that does not meet currently accepted standards of care. [10] [11] [12] [13] [14] [15] [16] The low accrual rate in CCTs has a significant effect on both the quality of research and the rate at which new scientific discoveries are made. 17, 18 Better representation of all those affected by cancer-including different races, ethnicities, age groups and income levels-is critical to producing more generalizable findings to the population as a whole. 8 The low accrual rate in CCTs-especially among ethnic and racial minorities, older adults and other medically underserved groups-is a matter of social justice. 6 Indeed, the principles of social justice, as articulated in the Belmont report on research involving human subjects, 22 demand better representation of all populations in CCTs to ensure the just distribution of the benefits and burdens of research participation. 20 A number of reports have observed that enhancing trial participation can address persistent disparities in cancer incidence, morbidity, and mortality.
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The literature has identified numerous barriers that negatively affect participation in cancer clinical research. 25 Experts have repeatedly noted that to both overcome these barriers and develop successful approaches to recruitment, such efforts A background paper articulating the rationale and goals of the project, along with a set of invited commentaries on the paper, 39 were shared with participants before the meeting.
To ensure a shared understanding of both CCTs and CBPR, orientation sessions on each topic were held. During the meeting, participants discussed the definition of community and who "represents" community, the need for improving community engagement in the CCT process, the pressures faced by cancer researchers and institutions, and how engagement works in other clinical research systems. In particular, participants examined the federally funded AIDS Clinical Trials Group, which has an analogous structure to the NCI National Cooperative Groups, 40 but has incorporated community engagement and CBPR principles since the late 1980s.
At this first of two gatherings, participants articulated a vision for the future and guiding principles for the development of the strategic plan, as described in Table 1 .
Participants adopted the definition of "community"
advanced by the Centers for Disease Control and Prevention:
those whose participation is necessary for the implementation of the research and whose well-being is likely to be affected by the conduct of the research. 41 For years, cancer patient advocates have been representing the cancer patient "community,"
providing critical input into the design and implementation of CCTs at both national and local levels. However, to reap the full benefit of community engagement in phase III CCTs, participants recommended that (1) the definition of community be expanded, such that communities disproportionately affected by cancer morbidity and mortality should also be well-represented (see side bar); (2) there should be a greater number of community representatives, and (3) their roles be systematized, strengthened, and made more inclusive. • Community Representatives have experience with the healthy population at risk and ideally are affiliated with a community-based organization or group whose constituency is disproportionately affected by cancer.
drafting and vetting the recommendations
• Patient Advocates have experience as a patient with cancer, caregiver, or family member and ideally are affiliated with a cancer advocacy organization or group. Acknowledge the many access barriers to CCTs that are beyond the scope of this project Acknowledge that federal research priorities impact the plan but are beyond the scope of this project
Acknowledge that we cannot fix all that may be broken about the U.S. health care system
Build upon efforts of those in the CCT system currently working to engage communities Challenge the CCT system to change, while also working within the system 4. Change is challenging and time consuming, but ultimately worth the effort: "The expectations outlined . . . will be challenging to meet, but the potential advance in individual and community understanding and use of research findings is great."
5. Test out these ideas: "Several pilots should be conducted."
Critical comments fell into six main categories: The report is the first to provide specific guidance as to why and how the CCT process should involve communities affected by cancer-from trial design to implementation to dissemination of results.. The report's fifty-eight recommendations fall into seven major categories (Table 3) and Table 2 
disseminATing And imPlemenTing The rePorT
The report dissemination process has involved a twopronged approach: outreach to key audiences through conferences and meetings, and support for groups seeking to implement specific recommendations.
outreach to Key Audiences
As the largest provider of publicly funded phase III CCTs, the NCI-sponsored Cooperative Groups were a key dissemination audience. Project staff presented at four Cooperative
Group semi-annual meetings. 42 Other audiences included institutional review boards, National Institutes of Health Clinical and Translational Science Awardees, NCI staff, and the American Cancer Society health disparities community.
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The AHRQ also invited a presentation on the report at its annual conference as the sole example of nonprofit organizations utilizing its evidence reports as a foundation for a policy change initiative. The results of these efforts will be reported in a subsequent report.
ChAllenges To imPlemenTing The reCommendATions
There are a number of challenges to implementing the report's recommendations. We have identified the main comments and criticisms that were raised during the vetting of the draft report recommendations. We now highlight the two challenges that have proven to be the most significant throughout this initiative and during the year since the report was released.
mistrust and lack of an organized Constituency to Advocate for Change
Unlike HIV/AIDS research, which has long had an expectation of community involvement from both the researcher and patient perspective, the same does not hold true for in cancer clinical research. Although cancer patient advocates have worked for years to gain influence within the CCT research system, they have been few in number, their influence is highly variable, and the mandate for their involvement is weak at best. Some researchers continue to question the need for their role, let alone expanding their ranks to include community representatives.
Seeking to achieve a unified vision among the five distinct constituencies assembled by this project proved challenging, despite several deliberate attempts to orient them to each other's perspectives and "world views." A significant portion of the first meeting was spent sharing perspectives on an established clinical research "system" that some participantsespecially those from community-based organizations-felt ready to challenge, whereas others-especially those working in the system-were quick to defend. In some cases, groups were skeptical of each others' motives and capabilities. Some CBPR experts did not view community engagement in CCTs as a high priority and were skeptical that CCTs could truly be 
ConClusion
For cancer clinical research to achieve its full potential in reducing cancer deaths and eliminating cancer disparities, it is imperative to foster greater community involvement in the design and implementation of CCTs. Communities must better understand how CCTs work, how members can be involved as participants and advisors, and how they can maximally benefit from the results. Similarly, researchers must better understand how communities are organized and function, how community involvement can benefit cancer research, and how to effectively engage communities in meaningful roles.
The Communities as Partners report calls for nothing less than a paradigm shift in the way CCTs are conducted.
